Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus

Toxicology and Applied Pharmacology

Volumn 280, Issue 2, 2014, Pages 362-369

  Qi, Yanxin ^a,b   Guo, Huanhuan ^b,c   Hu, Ningning ^b,d   He, Dongyun ^b,d   Zhang, Shi ^b,e   Chu, Yunjie ^f   Huang, Yubin ^a   Li, Xiao ^b,d   Sun, LiLi ^g   Jin, Ningyi ^b,d  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c Changchun Brother Biotech Co Ltd   (China)

^d Key Laboratory of Jilin Province for Zoonosis Prevention and Control   (China)

^e JILIN UNIVERSITY   (China)

^f The Breast Surgery   (China)

^g CHANGCHUN UNIVERSITY   (China)

Author keywords

Apoptin; Conditionally replicating adenovirus; Human telomerase reverse transcriptase; Safety evaluation

Indexed keywords

AD HTERT E1A APOPTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; APOPTIN; HEMOGLOBIN; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; CAPSID PROTEIN; E1A PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN; VP3 PROTEIN, CHICKEN ANEMIA VIRUS;

ACUTE TOXICITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEAGLE; BEHAVIOR CHANGE; BODY TEMPERATURE; BODY WEIGHT; BONE MARROW EXAMINATION; BREATHING; CANCER CELL; CARDIOVASCULAR SYSTEM; CATALEPSY; CONTROLLED STUDY; CONVULSION; DEATH; DIARRHEA; DIGESTIVE SYSTEM; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; ELECTROSHOCK SEIZURE; ERYTHROCYTE COUNT; EXOPHTHALMOS; EXPERIMENTAL DOG; EXPERIMENTAL GUINEA PIG; FEMALE; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HOT PLATE TEST; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE INFLAMMATION; INJECTION SITE ULCER; LACRIMATION; LOCOMOTION; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; MOUSE; MUSCLE FUNCTION; MUSCLE TONE; NERVOUS SYSTEM; NONHUMAN; PAIN; PROMOTER REGION; PTOSIS; QUALITY CONTROL; RAT; REFLEX; REPEATED DRUG DOSE; RESPIRATORY SYSTEM; RIGHTING REFLEX TEST; RISK ASSESSMENT; SALIVATION; SEDATION; SEROLOGY; SKIN COLOR; SLEEP TIME; SPLEEN WEIGHT; SYSTEMIC ANAPHYLAXIS; THROMBOCYTE COUNT; THYMUS; TOXICITY TESTING; TREMOR; VOCALIZATION; WRITHING TEST; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; DOG; GENE THERAPY; GENETICS; GUINEA PIG; ONCOLYTIC VIROTHERAPY; WISTAR RAT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CAPSID PROTEINS; DOGS; FEMALE; GENETIC THERAPY; GUINEA PIGS; MALE; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; RATS; RATS, WISTAR; TELOMERASE;

EID: 84908024297     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.08.008     Document Type: Article

References (45)

1. Bauerschmitz G.J., Barker S.D., Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int. J. Oncol. 2002, 21:1161-1174.
2. Bauerschmitz G.J., Kanerva A., Wang M., Herrmann I., Shaw D.R., Strong T.V., Desmond R., Rein D.T., Dall P., Curiel D.T. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int. J. Cancer 2004, 111:303-309.
3. Bazan-Peregrino M., Carlisle R., Hernandez-Alcoceba R., Iggo R., Homicsko K., Fisher K., Hallden G., Mautner V., Shen Y., Seymour L. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum. Gene Ther. 2008, 19:873-886.
4. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
5. Chailertvanitkul V.A., Pouton C.W. Adenovirus: a blueprint for non-viral gene delivery. Curr. Opin. Biotechnol. 2010, 21:627-632.
6. Choi J.W., Lee J.S., Kim S.W., Yun C.O. Evolution of oncolytic adenovirus for cancer treatment. Adv. Drug Deliv. Rev. 2012, 64:720-729.
7. Danen-Van Oorschot A., Fischer D., Grimbergen J.e, Klein B., Zhuang S.-M., Falkenburg J., Backendorf C., Quax P., Van der Eb A., Noteborn M. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. 1997, 94:5843-5847.
8. Dixit R., Boelsterli U.A. Healthy animals and animal models of human disease (s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov. Today 2007, 12:336-342.
9. Dong J.Y., Wang D., Van Ginkel F.W., Pascual D.W., Frizzell R.A. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther. 1996, 7:319-331.
10. Everts B., van der Poel H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005, 12:141-161.
11. Ganly I., Kirn D., Eckhardt S.G., Rodriguez G.I., Soutar D.S., Otto R., Robertson A.G., Park O., Gulley M.L., Heise C. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000, 6:798-806.
12. Greaves P., Williams A., Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 2004, 3:226-236.
13. Han S., Zhu Q., Ma J., Lv Y., Zhao J., Huang C., Jia X., Ou W., Guo H. Apoptin sensitizes radiation-induced cell death via classic mitochondrial, caspase and p53-dependent signaling in HepG2 cells. Mol. Med. Rep. 2011, 4:59.
14. Harris P., Dayan A. Designing a safety evaluation programme for gene therapy products: recommendations and the way forward. Hum. Exp. Toxicol. 1998, 17.
15. Kamen A., Henry O. Development and optimization of an adenovirus production process. J. Gene. Med. 2004, 6(Suppl. 1):S184-S192.
16. Kim D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert. Opin. Biol. Ther. 2001, 1.
17. Kitano Y., Usui C., Takasuna K., Hirohashi M., Nomura M. Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J. Pharmacol. Toxicol. Methods 1996, 35:25-29.
18. Lee J.M., Im W.J., Nam Y.J., Oh K.H., Lim J.C., Whang W.K., Sohn U.D. Acute toxicity and general pharmacological action of QGC EXT. Korean J. Physiol. Pharmacol. 2012, 16:49-57.
19. Litchfield J.T. Evaluation of the safety of new drugs bymeans of tests in animals. Clin. Pharmacol. Ther. 1962, 3:665-672.
20. Liu L., Wu W., Zhu G., Liu L., Guan G., Li X., Jin N., Chi B. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. International journal of molecular medicine. 2012, 30:747-754.
21. Los M., Panigrahi S., Rashedi I., Mandal S., Stetefeld J., Essmann F., Schulze-Osthoff K. Apoptin, a tumor-selective killer. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2009, 1793:1335-1342.
22. Maddika S., Panigrahi S., Wiechec E., Wesselborg S., Fischer U., Schulze-Osthoff K., Los M. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol. Cell. Biol. 2009, 29:1235-1248.
23. Makower D., Rozenblit A., Kaufman H., Edelman M., Lane M.E., Zwiebel J., Haynes H., Wadler S. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 2003, 9:693-702.
24. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., Landers S., Maples P., Romel L., Randlev B. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000, 60:6359-6366.
25. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., Kuhn J., McCarty T., Landers S., Blackburn A. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 2001, 19:289-298.
26. Newell D.R., Burtles S.S., Fox B.W., Jodrell D.I., Connors T.A. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br. J. Cancer 1999, 81:760-768.
27. Ouchi M., Kawamura H., Urata Y., Fujiwara T. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). Investig. New Drugs 2009, 27:241-245.
28. Palmer D., Mautner V., Kerr D. Clinical experience with adenovirus in cancer therapy. Curr. Opin. Mol. Ther. 2002, 4:423.
29. Park S.H., Sim Y.B., Kang Y.J., Lee J.K., Lim S.S., Suh H.W. Effect of Agrimonia pilosa ledeb extract on the antinociception and mechanisms in mouse. Korean J. Physiol. Pharmacol. 2012, 16:119-123.
30. Pietersen A., Seelen M., Erkeland S., Rutjes S., Philipsen S., Medema J.P., Noteborn M. Continuous apoptin expression in transgenic mice does not interfere with lymphocyte development and proliferation. Preclinical studies with Apoptin 2005, 93.
31. Reid T., Galanis E., Abbruzzese J., Sze D., Andrews J., Romel L., Hatfield M., Rubin J., Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001, 8:1618-1626.
32. Rohn J., Noteborn M. The viral death effector apoptin reveals tumor-specific processes. Apoptosis 2004, 9:315-322.
33. Salgado H.R.N., Roncari A.F.F., Moreira R.R.D. Antidiarrhoeal effects of Mikania glomerata Spreng. (Asteraceae) leaf extract in mice. Artigo 2005, 15:205-208.
34. Schoop R.A., de Jong R.J.B., Noteborn M.H. Apoptin induces apoptosis in an oral cancer mouse model. Cancer Biol. Ther. 2008, 7:1368-1373.
35. Su C., Cao H., Tan S., Huang Y., Jia X., Jiang L., Wang K., Chen Y., Long J., Liu X., Wu M., Wu X., Qian Q. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol. Sci. 2008, 106:242-250.
36. Van der Eb M.M., Pietersen A.M., Speetjens F.M., Kuppen P.J., van de Velde C.J., Noteborn M.H., Hoeben R.C. Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther. 2002, 9:53-61.
37. Varnavski A., Calcedo R., Bove M., Gao G., Wilson J. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005, 12:427-436.
38. Verdier F., Descotes J. Preclinical safety evaluation of human gene therapy products. Toxicol. Sci. 1999, 47:9-15.
39. Wang C., Zhang Y. Apoptin gene transfer via modified wheat histone H4 facilitates apoptosis of human ovarian cancer cells. Cancer Biother. Radiopharm. 2011, 26:121-126.
40. Xiao L., Yan L., Zhongmei W., Chang L., Huijun L., Mingyao T., Kuoshi J., Lili S., Pegn G., Encheng Y. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol. Cancer 2010, 9:10.
41. Xiechuan W., Xing F., Qingxiu W. Research on the Methods of Active Systemic Anaphylaxis on Guinea Pig in Drug Safety Evaluation. Chinese Journal of Comparative Medicine. 2012, 5:51-55.
42. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 2007, 7:141-148.
43. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 2007, 7:659-670.
44. Zhan H., Wang J.-S., Wang H.-F., Zuo Y.-G., Wang C.-H., Ding M.-X. Apoptin induces apoptosis in human bladder cancer EJ and BIU-87 cells. Asian Pac. J. Cancer Prev. 2012, 13:135-138.
45. Zhang M., Wang J., Li C., Hu N., Wang K., Ji H., He D., Quan C., Li X., Jin N. Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma. Int. J. Oncol. 2013, 42:1052-1060.